What are the recommended intra‑articular injection options, dosages, frequency, and contraindications for managing knee osteoarthritis when oral analgesics, physical therapy, weight control, and activity modification are insufficient?

Intra-articular Corticosteroid Injections for Knee Osteoarthritis

Intra-articular corticosteroid injections are the first-line injectable treatment for knee osteoarthritis when conservative measures fail, supported by 19 high-quality and 6 moderate-quality studies, though benefits typically last only 3 months. 1

Recommended Injectable Options (in order of evidence strength)

First-Line: Corticosteroid Injections

• Corticosteroids have the strongest evidence base among all intra-articular options for knee OA 1
• Particularly indicated for acute pain exacerbations, especially when accompanied by joint effusion 2, 3
• Provide significant pain relief and functional improvement lasting weeks to months 4, 5
• Triamcinolone hexacetonide is superior to triamcinolone acetonide and should be the preferred corticosteroid formulation 4

Dosing and Administration for Corticosteroids

• Knee joint dosing: 20-80 mg for large joints (methylprednisolone acetate) 6
• Alternative: 5-15 mg for knee joints (triamcinolone acetonide), with doses up to 40 mg for larger areas 7
• Inject directly into the synovial space using strict aseptic technique 6, 7
• Use 20-24 gauge needle; aspirate synovial fluid first if excessive effusion present 6
• Frequency: Repeat injections at intervals of 1-5 weeks depending on degree of relief obtained 6
• Single injections into multiple joints up to total of 80 mg have been given 7

Second-Line: Platelet-Rich Plasma (PRP)

• Consider PRP only after corticosteroid failure or in patients with mild-to-moderate OA 1
• Supported by 2 high-quality and 1 moderate-quality study showing reduced pain and improved function 1
• Critical caveat: PRP shows worse treatment response in severe knee OA (Kellgren-Lawrence grade 3-4) 1
• Concerns exist regarding cost and safety profile 1
• Network meta-analysis shows PRP has highest P-Score for WOMAC improvement at 6 months 8

NOT Recommended: Hyaluronic Acid

• The AAOS recommends AGAINST routine use of hyaluronic acid in knee OA 1
• Despite 17 high-quality and 11 moderate-quality studies, evidence is inconsistent 1
• Number needed to treat is 17 patients, but cannot identify which subset benefits 1
• The ACR provides no recommendation (evidence too equivocal) 9
• A 2023 high-quality RCT found no superior effect compared to placebo in patients with low baseline pain 10

Contraindications and Precautions

Absolute Contraindications

• Active joint infection or septic arthritis 6, 7
• Bacteremia or skin infection overlying injection site 6
• Known hypersensitivity to corticosteroid preparations 6, 7

Relative Contraindications and Warnings

• Diabetes mellitus: Risk of systemic hyperglycemia after corticosteroid injection 5
• Avoid injecting into tendon substance (causes tendon rupture); inject into tendon sheath only 6, 7
• Repeated corticosteroid injections may cause joint degradation and cartilage damage 5
• Anatomically inaccessible joints (spinal, sacroiliac) are unsuitable 6
• Use caution with hip joint injections due to proximity to large blood vessels 6

Post-Injection Monitoring

• Cover injection site with sterile dressing 6
• Move joint gently after injection to mix suspension with synovial fluid 6
• Monitor for signs of infection (septic arthritis is a known complication) 5
• Watch for local pain and swelling lasting a few days (common minor side effect) 11

Clinical Decision Algorithm

For patients failing oral NSAIDs, acetaminophen, physical therapy, and weight control:

1. If acute pain flare with effusion present: Intra-articular corticosteroid injection (20-80 mg methylprednisolone or 5-15 mg triamcinolone hexacetonide) 1, 2, 4

2. If chronic pain without severe radiographic changes (KL grade 1-2): Consider corticosteroid first; if inadequate response after 3 months, consider PRP 1, 8

3. If severe OA (KL grade 3-4): Corticosteroid injection only; avoid PRP due to poor response in severe disease 1

4. Avoid hyaluronic acid as routine treatment given inconsistent evidence and AAOS recommendation against it 1

Common Pitfalls to Avoid

• Failure to enter joint space is the most common cause of treatment failure 6
• Injecting into surrounding tissue rather than synovial cavity leads to tissue atrophy and no benefit 6
• Mixing corticosteroid suspension with other solutions causes physical incompatibilities 6
• Allowing suspension to settle in syringe before injection reduces efficacy 7
• Using inadequate needle length (minimum 1.5 inches for adults, longer for obese patients) 7
• Expecting benefits beyond 3 months from corticosteroid injections 1